前列腺特异性膜抗原在质瘤管理中的使用:过去,现在和未来
Joshua D McBriar1, Neeva Shafiian1, Stephen Scharf2
1From the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Clinical nuclear medicine
|July 5, 2024
概括
前列腺特异性膜抗原 (PSMA) 在通过成像和组织病理学来诊断和管理质瘤方面表现有前途. 在质瘤治疗中,需要对PSMA向治疗方法进行进一步的研究.
科学领域:
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
- 分子生物学分子生物学
背景情况:
- 前列腺特异性膜抗原 (PSMA) 是一种金属酶,在瘤新血管中高度表达,包括质瘤.
- 由于PSMA的细胞内内化能力,它成为提供治疗药物和放射性链体的有吸引力的目标.
- 用PSMA准质瘤新血管是诊断和管理的日益增长的研究领域.
研究的目的:
- 审查目前PSMA在质瘤组织病理学,成像和治疗中的应用.
- 探索PSMA在质瘤管理中的未来使用方向.
主要方法:
- 在2023年6月使用PubMed和Scopus数据库进行了一项文献综述.
- 搜索术语包括"PSMA"",前列腺特异性膜抗原"",PSMA PET"和各种质瘤相关术语.
- 从94篇选的文章中选择了61篇相关的出版物进行全面分析.
主要成果:
- PSMA PET成像是一种有前途且准确的 glioma 诊断和管理工具.
- PSMA 组织病理学可能作为结质瘤行为的预测工具.
- 初步数据表明,PSMA向疗法在质瘤治疗中可能有用,尽管需要更多的研究.
结论:
- PSMA PET成像对于结质瘤的诊断和管理是有效的.
- PSMA 组织病理学显示出预测质瘤行为的潜力.
- 针对PSMA的治疗方法需要进一步研究结质瘤治疗的有效性.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.